Farxiga Overview 2019: A Member of the Novel Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor Class
It is approved for the treatment of type 2 diabetes and currently in Phase III trials for the treatment of type 1 diabetes, as well as for chronic kidney disease including diabetic nephropathy.